Книги по МРТ КТ на английском языке / MRI for Orthopaedic Surgeons Khanna ed 2010
.pdf
|
|
17 Correlation of MRI with Other Imaging Studies 423 |
||
|
|
|
|
|
|
|
tained with conventional radiographs and MRI. However, |
||
■ Summary |
||||
for selected patients, the clinician must make the deci- |
||||
For the appropriate evaluation of a patient with muscu- |
sion to request other imaging studies, such as CT, nuclear |
|||
loskeletal disease, it is important for clinicians to use all |
scintigraphy, and positron emission tomography, as they |
|||
of the imaging tools and modalities in their armamen- |
are indicated. With time, one can expect improvements |
|||
tarium. E cacy, cost, availability, and patient limitations |
in technology and the development of new imaging mo- |
|||
all play roles in imaging modality selection. In most cases, |
dalities that can be integrated into diagnosis and treatment |
|||
most of the clinically important information can be ob- |
algorithms. |
References |
17. |
Santiago Restrepo C, Giménez CR, McCarthy K. Imaging of osteomy- |
|
|
|
|
elitis and musculoskeletal soft tissue infections: current concepts. |
1. |
Steinbach HL. The roentgen appearance of osteoporosis. Radiol Clin |
|
Rheum Dis Clin North Am 2003;29:89–109 |
|
North Am 1964;2:191–207 |
18. |
Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in |
2. |
Kamholtz R, Sze G. Current imaging in spinal metastatic disease. |
|
the detection of bone marrow infiltration in patients with plasma |
|
Semin Oncol 1991;18:158–169 |
|
cell neoplasms in comparison to the radiological skeletal survey. Eur |
3. |
Fayad LM, Johnson P, Fishman EK. Multidetector CT of musculo- |
|
Radiol 2006;16:1005–1014 |
|
skeletal disease in the pediatric patient: principles, techniques, and |
19. |
Mulligan ME. Myeloma update. Semin Musculoskelet Radiol |
|
clinical applications. Radiographics 2005;25:603–618 |
|
2007;11:231–239 |
4. |
Fayad LM, Bluemke DA, Fishman EK. Musculoskeletal imaging with |
20. |
Masala S, Schillaci O, Massari F, et al. MRI and bone scan imag- |
|
computed tomography and magnetic resonance imaging: when is |
|
ing in the preoperative evaluation of painful vertebral fractures |
|
computed tomography the study of choice? Curr Probl Diagn Radiol |
|
treated with vertebroplasty and kyphoplasty. In Vivo 2005;19: |
|
2005;34:220–237 |
|
1055–1060 |
5. |
Genant HK, Wilson JS, Bovill EG, Brunelle FO, Murray WR, Rodrigo JJ. |
21. |
Maynard AS, Jensen ME, Schweickert PA, Marx WF, Short JG, Kallmes |
|
Computed tomography of the musculoskeletal system. J Bone Joint |
|
DF. Value of bone scan imaging in predicting pain relief from percu- |
|
Surg Am 1980;62:1088–1101 |
|
taneous vertebroplasty in osteoporotic vertebral fractures. AJNR Am |
6. |
Wilson JS, Korobkin M, Genant HK, Bovill EG Jr. Computed tomo- |
|
J Neuroradiol 2000;21:1807–1812 |
|
graphy of musculoskeletal disorders. AJR Am J Roentgenol |
22. |
Fernandez-Ulloa M, Klostermeier TT, Lancaster KT. Orthopaedic |
|
1978;131:55–61 |
|
nuclear medicine: the pelvis and hip. Semin Nucl Med 1998;28:25– |
7. |
Geijer M, El-Khoury GY. MDCT in the evaluation of skeletal trauma: |
|
40 |
|
principles, protocols, and clinical applications. Emerg Radiol |
23. |
Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the |
|
2006;13:7–18 |
|
detection, grading and response to therapy of soft tissue and bone |
8. |
Newton PO, Hahn GW, Fricka KB, Wenger DR. Utility of three- |
|
sarcomas; a systematic review and meta-analysis. Cancer Treat Rev |
|
dimensional and multiplanar reformatted computed tomography |
|
2004;30:83–101 |
|
for evaluation of pediatric congenital spine abnormalities. Spine |
24. |
Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign |
|
(Phila Pa 1976) 2002;27:844–850 |
|
and malignant musculoskeletal lesions. Skeletal Radiol 2003;32: |
9. |
Mui LW, Engelsohn E, Umans H. Comparison of CT and MRI in pa- |
|
201–208 |
|
tients with tibial plateau fracture: can CT findings predict ligament |
25. |
Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith |
|
tear or meniscal injury? Skeletal Radiol 2007;36:145–151 |
|
MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl |
10. |
Lee E, Worsley DF. Role of radionuclide imaging in the orthopedic |
|
Med 1999;26:22–30 |
|
patient. Orthop Clin North Am 2006;37:485–501 |
26. |
Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. |
11. |
McCarthy EF, Frassica FJ. Diagnosing bone disease. In: McCarthy EF, |
|
Clinical value of [18-F] fluorodeoxyglucose positron emission |
|
Frassica FJ, eds. Pathology of Bone and Joint Disorders: With Clinical |
|
tomography imaging in soft tissue sarcomas. Ann Surg 2000;231: |
|
and Radiographic Correlation. Philadelphia: WB Saunders; 1998:1–24 |
|
380–386 |
12. |
Abdel-Dayem HM. The role of nuclear medicine in primary bone and |
27. |
Schmitz A, Risse JH, Textor J, et al. FDG-PET findings of vertebral |
|
soft tissue tumors. Semin Nucl Med 1997;27:355–363 |
|
compression fractures in osteoporosis: preliminary results. Osteo- |
13. |
Deutsch AL, Coel MN, Mink JH. Imaging of stress injuries to bone. |
|
poros Int 2002;13:755–761 |
|
Radiography, scintigraphy, and MR imaging. Clin Sports Med |
28. |
Shin DS, Shon OJ, Byun SJ, Choi JH, Chun KA, Cho IH. Di erentia- |
|
1997;16:275–290 |
|
tion between malignant and benign pathologic fractures with F-18- |
14. |
Greenspan A, Stadalnik RC. A musculoskeletal radiologist’s view of |
|
fluoro-2-deoxy-D-glucose positron emission tomography/computed |
|
nuclear medicine. Semin Nucl Med 1997;27:372–385 |
|
tomography. Skeletal Radiol 2008;37:415–421 |
15. |
Alazraki NP. Radionuclide imaging in the evaluation of infections |
29. |
Delank KS, Schmidt M, Michael JWP, Dietlein M, Schicha H, Eysel |
|
and inflammatory disease. Radiol Clin North Am 1993;31:783–794 |
|
P. The implications of 18F-FDG PET for the diagnosis of endopros- |
16. |
El-Maghraby TAF, Moustafa HM, Pauwels EKJ. Nuclear medicine |
|
thetic loosening and infection in hip and knee arthroplasty: re- |
|
methods for evaluation of skeletal infection among other diagnostic |
|
sults from a prospective, blinded study. BMC Musculoskelet Disord |
|
modalities. Q J Nucl Med Mol Imaging 2006;50:167–192 |
|
2006;7:20–28 |
426 |
V Special Considerations |
|
|
(e.g., iron, nickel, and martensitic stainless steel) concentrate |
Implant Safety Profiles |
|
and retain magnetism the most, resulting in severe distor- |
The FDA requires testing of all implants to evaluate their |
|
tion of the images. Paramagnetic or weakly ferromagnetic |
|
|
safety profiles and classify them as MRI safe, condition- |
|
|
materials (e.g., platinum) have a minimal e ect on mag- |
|
|
ally safe, or unsafe. The list of these devices is extensive |
|
|
netic field homogeneity and result in less image distortion. |
|
|
and constantly changing, especially as more objects are |
|
|
Diamagnetic materials (e.g., zinc, gold, and copper) do not |
|
|
tested at 3 T and higher, precluding a complete review of |
|
|
a ect or a ect only minimally the static or local magnetic |
|
|
these devices in this chapter. A regularly updated list of re- |
|
|
fields. |
|
|
viewed implants and devices is available online at http:// |
|
|
|
|
|
Metallic Objects in Magnetic Fields |
www.MRIsafety.com. It is important to be aware of devices |
|
that absolutely contraindicate MRI scanning, including the |
|
|
The clinical value of an MRI examination in a patient with |
following: |
|
|
|
|
metallic hardware depends on the proximity of the hard- |
• Implantable cardiac defibrillators |
|
ware to the site of interest. For example, one can anticipate a |
|
|
• Cardiac pacemakers |
|
|
limited evaluation of neural foramina adjacent to an anterior |
|
|
• Implantable medication infusion pumps |
|
|
cervical fusion or an inability to detect an epidural abscess |
|
|
• Ferromagnetic aneurysm clips (e.g., stainless steel) |
|
|
adjacent to pedicle screw instrumentation. Newer pulse se- |
|
|
• Poppen-Blaylock carotid artery clamps |
|
|
quences have been developed that allow for imaging in the |
|
|
• Spinal/bone fusion stimulators |
|
|
presence of metallic implants (see Chapter 16). Myelography |
|
|
• Cochlear implants |
|
|
remains a viable alternative for the postoperative spine. CT |
|
|
• Tissue expanders |
|
|
also is a valuable alternative in postoperative patients, par- |
|
|
• Gastric electrical stimulation devices |
|
|
ticularly in conjunction with myelography. |
|
|
|
|
|
In addition to causing distortion of images, some metal- |
Certain models of some devices (e.g., implantable cardiac |
|
lic foreign bodies or surgical implants can move or gener- |
defibrillators, cardiac pacemakers, spinal/bone fusion |
|
ate heat in the presence of a magnetic field, possibly leading |
stimulators, and cochlear implants) may be scanned under |
|
to injury or death.9,10 For this reason, each patient must be |
strict criteria. However, many MRI centers still consider as |
|
screened for metallic objects within the body, usually with a |
absolute contraindications the presence of such devices or |
|
verbal interview and a written checklist. |
of devices that do not meet the required technical condi- |
|
Of particular concern are metallic foreign bodies within |
tions (see below). Of note, the Starr-Edwards Model Pre- |
|
the orbit that may dislodge and rupture the globe or dam- |
6000 heart valve prosthesis (Baxter Healthcare, Santa Ana, |
|
age the optic nerve. To our knowledge, there is only one re- |
CA) is now designated as conditionally MRI safe, although |
|
ported case of a patient who su ered a vitreous hemorrhage, |
previously it was thought to be an absolute contraindication |
|
caused by a dislodged metal fragment (2.0 × 3.5 mm), that |
to an MRI examination.13 In recent years, multiple in vitro |
|
led to blindness.11 Although it is standard for MRI facilities to |
and in vivo controlled studies have shown increasing evi- |
|
prescreen for metallic orbital foreign bodies, methods of ac- |
dence that some patients with cardiac pacemakers can be |
|
complishing this screening vary. Conventional radiographs |
scanned safely under specific conditions, despite the poten- |
|
of the orbits are said to detect metallic fragments as small as |
tial for arrhythmia and death.14–18 However, in most situa- |
|
0.1 × 0.1 × 0.1 mm. However, there is debate over which pa- |
tions, a pacemaker remains an absolute contraindication for |
|
tients should be referred for conventional radiographs. Many |
MRI unless the procedure is an orchestrated e ort between |
|
MRI centers obtain orbital radiographs of patients with an |
cardiology and radiology, with informed consent of the |
|
occupational history of welding, but some experts advocate |
patient.19,20 |
|
obtaining films only if the patient is aware of a previous or- |
Similar caution is warranted for patients with neurostim- |
|
bital exposure to metal without removal of the fragment by |
ulation systems for deep brain stimulation of the thalamus, |
|
an ophthalmologist.12 At the authors’ institution, patients |
globus pallidus, and subthalamic nucleus as a treatment for |
|
with a history of working with metal undergo screening |
movement disorders. Although many patients have been |
|
orbital conventional radiographs. Alternatively, review of a |
scanned successfully without incident, there are specific |
|
previous CT scan, including the entirety of the orbits, is often |
guidelines regarding the technique.21,22 Currently, the Pul- |
|
considered su cient. |
sar Cochlear Implant (MED-EL Corp., Durham, NC) can be |
|
In addition to assessing for orbital foreign bodies, the cli- |
scanned, but only under specific conditions on a 0.2-T ma- |
|
nician should question the patient regarding any history of |
chine. The Nucleus 24 Auditory Brainstem Implant System |
|
metallic foreign bodies near other vital structures, such as |
(Cochlear Corp., Englewood, CO) has a removable magnet |
|
the lungs or spinal cord. For example, bullet fragments in the |
and may be scanned up to 1.5 T, again under specific condi- |
|
spinal canal contraindicate MRI because they may be ferro- |
tions. It is suggested that the manufacturer of these cochlear |
|
magnetic. |
devices be contacted before imaging.23 In general, imaging of |
18 MRI Safety 427
deep-brain stimulators and this specific implant should be |
Superficial Metal |
|
performed only after discussion with a neurologist and radi- |
There are safety concerns not only with internal metallic |
|
ologist. There are six specific requirements that also must be |
||
devices but also with skin surface metal, such as medicine |
||
met to obtain an MRI study of a patient with a spinal/bone |
||
patches containing a metal foil, surgical staples, tattoos, |
||
fusion stimulator24,25: |
||
• Cathodes of the implantable spinal fusion stimulator |
or permanent cosmetics. It is standard practice to remove |
|
transdermal medicine patches containing metallic foil at the |
||
should be a minimum of 1 cm from nerve roots. |
time of an MRI. Tope and Shellock31 reviewed the results of a |
|
• Conventional radiographs should be obtained before |
questionnaire given to 1032 patients with cosmetic tattoos. |
|
MRI to verify that there are no broken leads for the im- |
Only two patients experienced any sensory consequences |
|
plantable spinal fusion stimulator. |
(i.e., “slight tingling” or a “burning” sensation). These sen- |
|
• The study should be obtained on an MRI system |
sations are thought to be caused by heating from iron ox- |
|
with static fields of 1.5 T or less, avoiding pulse se- |
ide or other metal-based pigment. The FDA Center for Food |
|
quences that expose patient to high levels of RF |
Safety and Applied Nutrition, O ce of Cosmetics and Colors |
|
energy. |
fact sheet states, “The risks of avoiding an MRI when your |
|
• The patient should be observed continuously. |
doctor has recommended one are likely to be much greater |
|
• To reduce artifact, the implantable spinal fusion stim- |
than the risk of complications from the interaction between |
|
ulator should be placed as far from the spinal canal and |
the MRI and tattoo or permanent makeup.”32 Most prac- |
|
bone graft as possible. |
tices agree that an ice pack or cold compress can be applied |
|
• Selected imaging techniques, such as the use of FSE |
during scanning to the site of the tattoo, permanent cos- |
|
pulse sequences, should be used to reduce artifact. |
metics, or surgical staples to reduce the chance of thermal |
|
In the past, residual pacing wires also were considered to be |
injury. |
|
|
||
a contraindication to MRI. However, the current consensus |
|
|
is that such patients may undergo MRI if the wires are cut |
External Metallic Objects |
|
short (flush with skin) and there are no loops of wire outside |
In addition to precautions about internal foreign bodies, MRI |
|
the patient. Again, consultation with the patient’s cardiolo- |
||
gist may be necessary.26 |
centers screen for external metallic devices that may become |
|
Devices that are conditionally safe for MRI are implants |
projectiles in the MRI suite. Injuries and death have occurred |
|
that may be scanned if certain guidelines are satisfied. |
when large metallic objects, such as a ferrous oxygen tank, |
|
These devices include weakly magnetic intravascular fil- |
have been brought into the MRI suite.33–35 Even small objects |
|
ters, stents, and coils. MRI of patients with such devices |
that may not seem dangerous to many patients, such as jew- |
|
may require a waiting period of 6 to 8 weeks after implan- |
elry or hairpins, can become projectiles and cause injury. It |
|
tation to ensure that movement of the device caused by the |
is standard procedure to ask patients to remove such objects |
|
magnetic field does not disturb its implantation onto the |
and to empty their pockets. |
|
vessel wall.27,28 The evolving list of all such devices is be- |
|
|
yond the scope of this chapter, but in general, one should |
|
|
acquire additional information (e.g., brand name of the de- |
■ Pregnancy |
|
|
||
vice and date of implantation) for patients who have under- |
|
|
gone recent placement of such devices. Many MRI centers |
Although there are no known deleterious e ects of an MRI |
|
require documentation of this information before scanning |
examination during pregnancy, concerns about potential |
|
is allowed. |
side e ects remain. One such concern is that electromag- |
|
Devices that are safe for MRI are those known to produce |
netic fields could disrupt cell division. Because cell division |
|
no clinically significant hazard in the MRI environment. In |
is more rapid in the first trimester, it usually is acceptable to |
|
general, these devices have no electronically or magnetically |
delay MRI until after the first trimester. |
|
activated component, are made from a nonferromagnetic |
Because of such potential complications, MRI during |
|
material (such as titanium or nitinol), and may undergo |
pregnancy is obtained on a case-by-case basis, weighing |
|
MRI scanning at ≤1.5 T immediately after implantation.29,30 |
the risk and benefit for each examination; this procedure |
|
Many of these devices have been tested in the 3-T environ- |
is the accepted standard of care advocated by the American |
|
ment. It is important to obtain the brand name of the device |
College of Radiology.36 Shellock and Kanal37 have suggested |
|
from patients (who may have the package insert) or from |
that “MR imaging may be used in pregnant women if other |
|
their records. Safe devices also include orthopaedic implants |
nonionizing forms of diagnostic imaging are inadequate or if |
|
firmly placed within the bone because, although they may |
the examination provides important information that would |
|
be weakly magnetic, they do not dislodge or generate sub- |
otherwise require exposure to ionizing radiation.” In almost |
|
stantial heat. |
all institutions, written, informed consent is obtained. |
428 |
|
V Special Considerations |
|
|
|
|
|
|
alysis within 2 days of gadolinium administration. The tim- |
|
|
■ Contrast |
||
|
|
ing of dialysis relative to gadolinium administration may be |
||
|
|
MRI contrast agents are often used in the postoperative pa- |
critical for the prevention of this disease, but thus far little |
|
|
|
tient to evaluate for infection or scar tissue, in patients with |
is known regarding the e ectiveness of dialysis in reducing |
|
|
|
known or suspected musculoskeletal tumors, and for MR |
the risk of nephrogenic systemic fibrosis.43 At the authors’ |
|
|
|
angiography of the carotid and peripheral arteries. The gad- |
institution, a creatinine/estimated glomerular filtration rate |
|
|
|
olinium ion contains seven unpaired electrons in the outer |
measurement is currently obtained for patients at risk for |
|
|
|
shell, providing a large magnetic moment. This paramag- |
renal dysfunction, including those ≥65 years old or with a |
|
|
|
netic property enhances the relaxation rates of nearby water |
history of diabetes, those with renal disease or transplanta- |
|
|
|
protons. Although gadolinium itself is toxic, chelation with |
tion, and those with liver disease or hepatorenal syndrome. |
|
|
|
other substances makes it nontoxic and usable as a contrast |
In pregnant patients, contrast agents cross the placenta, |
|
|
|
agent. Over time, within the body, the free gadolinium ion |
enter the fetal collecting system, and then are excreted into |
|
|
|
can dissociate from its chelate. Normally, the amount of free |
the amniotic fluid. To the authors’ knowledge, no studies |
|
|
|
ions is low because of rapid clearance through the kidney. |
show the clearance rate of MRI contrast agents in the fetus, |
|
|
|
In addition to screening for the specific populations listed |
but it is possible that a chelated gadolinium agent could stay |
|
|
below, it is important to obtain a patient’s allergy history, |
within the amniotic fluid long enough to allow toxic free |
||
|
especially with regard to whether the patient had a reaction |
ions to accumulate. Gadolinium-based intravenous MR con- |
||
|
to gadolinium contrast previously and, if so, the nature of |
trast is labeled by the FDA as a category C medication; that |
||
|
that reaction. A history of a mild reaction (such as hives) to |
is, there is a lack of controlled studies with which to evaluate |
||
|
gadolinium generally requires premedication with predni- |
the e ects. Contrast is generally not administered to preg- |
||
|
sone and diphenhydramine. A history of reactions as severe |
nant patients unless the potential benefit outweighs its risks |
||
|
as respiratory or circulatory compromise is a contraindica- |
and unless written, informed consent has been obtained.20,44 |
||
|
tion to the use of MRI contrast. An adverse reaction to MRI |
The theoretic risk of free ion accumulation is smaller if the |
||
|
contrast is rare and generally expected to occur in less than |
agent is administered toward the end of gestation in the |
||
|
1% of patients.38 Reactions range from headache to weakness |
third trimester, leaving less time for dissociation and accu- |
||
|
and, very rarely, anaphylaxis.38 |
mulation of free ions before fetus delivery. |
||
|
|
For patients with renal failure, there is concern that de- |
When a breast-feeding mother receives contrast, it is |
|
|
|
creased renal clearance may result in accumulating free ion |
expected that most of the contrast will have cleared by 24 |
|
|
|
levels and toxicity. Clinicians usually recommend that a |
hours, leaving minimal residual contrast (<0.04%) to be ex- |
|
|
|
patient undergo dialysis within 24 hours after contrast ad- |
creted into the breast milk.20,45 However, a breast-feeding |
|
|
|
ministration. The FDA recently issued an alert for the use of |
woman should be given the option to abstain from breast- |
|
|
|
gadolinium intravenous contrast in patients with advanced |
feeding for 24 hours and to pump and discard breast milk for |
|
|
|
renal failure (i.e., those currently requiring dialysis or with an |
this time period. |
|
|
|
estimated glomerular filtration rate of <30 mL/min/1.73m2) |
Other patient populations have a theoretic risk of toxic- |
|
|
|
because of the risk of inducing nephrogenic systemic fibrosis/ |
ity from gadolinium, although no direct clinical evidence has |
|
|
|
nephrogenic fibrosing dermopathy.39 |
been established. For example, patients with elevated levels |
|
|
|
Nephrogenic systemic fibrosis/nephrogenic fibrosing der- |
of copper (such as those with Wilson disease) or zinc may |
|
|
|
mopathy is a progressive and sometimes fatal disease seen in |
have increased free ion accumulation after contrast adminis- |
|
|
|
patients with reduced renal function, and it causes fibrosis of |
tration because these metals may compete with gadolinium |
|
|
|
the skin and connective tissues throughout the body, includ- |
for the chelate. In vivo studies suggest that gadolinium ad- |
|
|
|
ing muscles of the extremities or abdomen, the diaphragm, |
ministration can lead to vasoocclusive complications in pa- |
|
|
|
and pulmonary vessels. Gadolinium has been detected in the |
tients with sickle cell disease because deoxygenated sickle |
|
|
|
soft tissues of several patients with nephrogenic systemic |
erythrocytes align perpendicularly to a magnetic field.46,47 |
|
|
|
fibrosis who were exposed to it as a radiographic contrast |
However, no clinical evidence suggests that these agents |
|
|
|
agent, supporting its association with this disease.40 Deo et |
precipitate a sickle cell crisis. Some facilities consider sickle |
|
|
al41 studied a population of end-stage renal disease patients |
cell disease to be a contraindication to the administration of |
||
|
|
for 18 months and found that each radiologic study that used |
gadolinium. |
|
|
|
a gadolinium-based contrast agent presented a 2.4% risk for |
Physicians, both clinicians and radiologists, are often |
|
|
|
nephrogenic systemic fibrosis. Broome et al42 reported an |
faced with the decision to give gadolinium contrast to a pa- |
|
|
|
odds ratio of 22.3 (95% confidence interval; range, 1.3 to |
tient with a history of an allergy to ionic contrast agents, |
|
|
|
378.9) for the development of nephrogenic systemic fibrosis |
such as those used for CT. Studies have shown that patients |
|
|
|
after gadolinium exposure in 168 dialysis patients. An impor- |
with a history of an ionic contrast allergy are at a higher risk |
|
|
|
tant observation in that study was that 10 of the 12 patients |
for a reaction, as are those with asthma and multiple medi- |
|
|
|
who developed nephrogenic systemic fibrosis underwent di- |
cation allergies.38,48 Often, MRI centers will require consent |